July 8, 2024 – Theralase® is pleased to announce that it has successfully closed its first tranche of a Non-Brokered Private Placement (“NBPP”) offering (“Offering”) of units (“Units”).
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
Toronto, Ontario – January 15th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs”) for the safe and effective destruction of various cancers, bacteria and viruses is providing an update regarding its Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”). To date, Study II has provided the primary study treatment for 63 patients. In 2016, Kamat et al. stated in the Journal of Clinical Oncology that the International Bladder Cancer Group (“IBCG”) recommended that, “Single-arm designs may be relevant for the BCG-unresponsive population. Here, a clinically meaningful initial complete response rate (for carcinoma in situ) or recurrence-free rate (for papillary tumors) of at least 50% at 6 months, 30% at 12 months and 25% at 18 months is recommended.”[1] Based on the 63 patients treated to … Read More